# A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy

Source: https://onco.cc/trials/nct06830889/  
OnCo record `nct06830889` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Trastuzumab brengitecan, Trastuzumab emtansine in her2-positive breast cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy is a phase 3 interventional study registered as NCT06830889 by Sichuan Baili Pharmaceutical Co., Ltd., with 1450 participants planned, started 2025-06-03 and due to reach its primary completion in 2031-10. Interventions recorded: BL-M07D1, T-DM1. Conditions listed: HER2-positive Breast Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06830889
- Phase: 3
- Setting: A Randomized Controlled Phase Ill Clinical Study of BL-M07D1 for Injection Versus Trastuzumab Emtansine (T-DM1) in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Enrolled: 1450

## Sources

- ClinicalTrials.gov NCT06830889: https://clinicaltrials.gov/study/NCT06830889

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- drugs: [Trastuzumab brengitecan](https://onco.cc/drugs/trastuzumab-brengitecan/), [Trastuzumab emtansine](https://onco.cc/drugs/trastuzumab-emtansine/)
- companies: [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/)

---
JSON: https://onco.cc/api/v1/entities/nct06830889.json